Amicus Begin Period Cash Flow from 2010 to 2024
| FOLD Stock | USD 9.36 0.79 7.78% |
Begin Period Cash Flow | First Reported 2007-03-31 | Previous Quarter 209.8 M | Current Value 212.4 M | Quarterly Volatility 91.7 M |
Check Amicus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.3 M, Interest Expense of 52.7 M or Other Operating Expenses of 496.5 M, as well as many indicators such as Price To Sales Ratio of 9.96, Dividend Yield of 0.0 or PTB Ratio of 27.46. Amicus financial statements analysis is a perfect complement when working with Amicus Therapeutics Valuation or Volatility modules.
Amicus | Begin Period Cash Flow |
Latest Amicus Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Amicus Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Amicus Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amicus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Amicus Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 89,456,325 | |
| Geometric Mean | 49,736,017 | |
| Coefficient Of Variation | 82.02 | |
| Mean Deviation | 60,642,717 | |
| Median | 69,485,000 | |
| Standard Deviation | 73,370,773 | |
| Sample Variance | 5383.3T | |
| Range | 249.2M | |
| R-Value | 0.73 | |
| Mean Square Error | 2714.5T | |
| R-Squared | 0.53 | |
| Significance | 0 | |
| Slope | 11,963,831 | |
| Total Sum of Squares | 75365.8T |
Amicus Begin Period Cash Flow History
About Amicus Therapeutics Financial Statements
Amicus Therapeutics stakeholders use historical fundamental indicators, such as Amicus Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Amicus Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amicus Therapeutics' assets and liabilities are reflected in the revenues and expenses on Amicus Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amicus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 153.1 M | 79.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out the analysis of Amicus Therapeutics Correlation against competitors. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.